To hear about similar clinical trials, please enter your email below
Trial Title:
tReatment Individualisation By EBV stratificatiON in Nasopharyngeal Carcinoma: an Umbrella Platform Study (RIBBON-Umbrella)
NCT ID:
NCT05517135
Condition:
Nasopharyngeal Carcinoma
Conditions: Official terms:
Carcinoma
Nasopharyngeal Carcinoma
Conditions: Keywords:
Nasopharyngeal Carcinoma
EBV DNA
Biomarker-guided
Treatment Individualization
Risk Stratification
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Other
Intervention name:
Arm 1
Description:
Concurrent chemoradiotherapy (CCRT) using cisplatin (100 mg/m2 IV) or carboplatin (AUC 5
IV) with radiotherapy +/- adjuvant chemotherapy (AC). For AC, physicians can choose
between cisplatin-5FU d1-4, q4w for 3 cycles, or capecitabine 650 mg/m2 bid for 12 months
or 1000 mg/m2 bid oral, d1-21, q3w for 6 months
Arm group label:
Arm 1
Intervention type:
Other
Intervention name:
Arm 2
Description:
IC using cisplatin (80 mg/m2 IV) or carboplatin (AUC 3-5 IV) in combination with
gemcitabine (1000 mg/m2 d1,8) or 5-fluorouracil (1000 mg/m2 bolus IV d1-4) or docetaxel
(75 mg/m2 IV), and CCRT +/- metronomic capecitabine (650 mg/m2 bid oral for 12 months)
Arm group label:
Arm 2
Intervention type:
Other
Intervention name:
Arm 3
Description:
IC using cisplatin (80 mg/m2 IV) or carboplatin (AUC 3-5 IV) in combination with
gemcitabine (1000 mg/m2 d1,8) or 5-fluorouracil (1000 mg/m2 bolus IV d1-4) or docetaxel
(75 mg/m2 IV), followed by either of the following:
1. RIBBON-LA-01 (NCT06093061)
2. CCRT + metronomic capecitabine (650 mg/m2 bid oral for 12 months)
Arm group label:
Arm 3
Intervention type:
Other
Intervention name:
Group 1
Description:
Combination chemotherapy (using cisplatin or carboplatin with gemcitabine, 5-fluorouracil
or docetaxel) and consolidative RT to the nasopharynx and neck (if good response to
chemotherapy) +/- metastasis-directed therapy (surgery, radiofrequency ablation or RT)
+/- immune checkpoint blockade (ICB) or capecitabine
Arm group label:
Group 1
Intervention type:
Other
Intervention name:
Group 2
Description:
Combination chemotherapy (using cisplatin or carboplatin with gemcitabine, 5-fluorouracil
or docetaxel) with or without ICB +/- maintenance ICB or capecitabine
Arm group label:
Group 2
Summary:
This is a prospective platform study that will investigate the outcomes of patients with
locoregionally-advanced nasopharyngeal carcinoma (LA-NPC) or recurrent-metastatic
nasopharyngeal carcinoma (RM-NPC) who are assigned to treatment arms of different
chemotherapy sequencing and intensity based on their pre- and on-treatment plasma EBV DNA
results.
Detailed description:
The primary objectives of this platform are: (1) to prospectively validate the prognostic
potential of an EBV DNA-based risk-stratification strategy of patients with LA- and
RM-NPC; and (2) to test if treatment individualization strategies based on pre- and
on-treatment plasma EBV DNA will improve survival outcomes.
For LA-NPC, the study design consists of two components: (1) to allocate adult patients
with UICC/AJCC 8th edition TNM-stage 2-4A LA-NPC to 3 treatment arms of different
intensities by their plasma EBV DNA levels pre-treatment and post-induction chemotherapy
(IC); and (2) to incorporate open-label, single-arm, phase 2 trials within the platform
for patients who are deemed to be at high-risk of relapse, defined by a persistently
detectable EBV DNA following 3 cycles of IC. Primary study end-point is 2-year
disease-free survival (DFS).
Criteria for eligibility:
Study pop:
Patients with suspected NPC or histologically confirmed NPC will be recruited for the
study. Patients with confirmed stage 2-4B NPC will be enrolled into the platform study.
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
Each patient eligible to participate in this study must meet all the following criteria:
1. Able to provide written informed consent and can understand and agree to comply with
the requirements of the study and the schedule of assessments.
2. Age ≥21 years on the day of signing the ICF
3. Fulfil one of the following three scenarios:
1. Suspected NPC cases, diagnosed clinically based on symptoms (neck swelling,
unilateral epistaxis, nasal obstruction etc.)
2. Newly-diagnosed, histologically confirmed NPC patients with Stages 2-4A disease
based on the AJCC/UICC 8th Edition TNM stage classification
3. Newly-diagnosed patients with RM-NPC
All confirmed NPC patients must meet these additional criteria before they can
continue participation in the study:
4. NPC associated with EBV infection, determined as:
1. The presence of EBV has been confirmed in the tumour by immunohistochemistry
for EBV antigens or in situ hybridization for EBV early RNA (EBER), or
2. NPC occurred in association with a raised serum titre of IgA to EBV viral
capsid antigen (VCA) or early antigen (EA) in a patient living in endemic area
of high incidence of EBV+ undifferentiated NPC, or
3. NPC in the context of an elevated circulating EBV genome level
5. AJCC 8th edition stage 2-4A or RM NPC based on the following diagnostic workup:
1. Evaluation of tumour extent with magnetic resonance imaging (MRI) of the
nasopharynx and neck. If MRI is medically contraindicated, computed tomography
(CT) scan with ≤3 mm and intravenous contrast is acceptable.
2. Distant metastasis staging:
- CT scan with contrast of the chest, abdomen, and pelvis or a total body
18F-Fluorodeoxygenase positron emission tomography CT (18F-FDG-PET-CT)
scan;
- Bone scan, if a 18F-FDG-PET-CT scan is not performed.
6. ECOG Performance Status ≤1
7. Adequate organ function
Exclusion Criteria:
Patients who meet any of the following criteria are not eligible to enrol:
1. Age <21 years or >99 years old
2. Has received any prior RT or systemic anti-cancer therapy including investigational
agents that are not part of the intended treatment plan for NPC
3. Any known central nervous system metastases and/or carcinomatous meningitis
4. Any active malignancy ≤2 years before start of study except for the specific cancer
under investigation in this study and any locally recurring cancer that has been
treated curatively (e.g., resected basal or squamous cell skin cancer, superficial
bladder cancer, carcinoma in situ of the cervix or breast)
5. Patients with severe chronic or active infections requiring systemic antibacterial,
antifungal or antiviral therapy, including tuberculosis infection, etc.
a. Severe infections within 4 weeks before start of study, including but not limited
to hospitalization for complications of infection, bacteremia, or severe pneumonia.
6. Patients with untreated chronic hepatitis B or chronic hepatitis B virus (HBV)
carriers whose HBV DNA is >500 IU/mL or patients with active hepatitis C virus (HCV)
should be excluded.
Note: Inactive hepatitis B surface antigen (HBsAg) carriers, treated and stable
hepatitis B (HBV DNA <500 IU/mL), and cured hepatitis C patients can be enrolled
7. Prior allogeneic stem cell transplantation or organ transplantation
8. Any of the following cardiovascular risk factors:
1. Cardiac chest pain, defined as moderate pain or any cardiac condition e.g.,
arrhythmias, malignant hypertension, etc. that limits instrumental activities
of daily living, ≤28 days before start of study
2. Pulmonary embolism ≤28 days before start of study
3. Any history of cerebrovascular accident or seizure ≤ 28 days before start of
study
9. A history of severe hypersensitivity reactions to gemcitabine, cisplatin,
capecitabine and/or any of its excipients
10. Has received any herbal medicine used to control cancer within 14 days of the start
of study
11. Patients with toxicities (as a result of prior anticancer therapy) which have not
recovered to baseline or stabilized, except for adverse events (AEs) not considered
a likely safety risk (eg, alopecia, neuropathy and specific laboratory
abnormalities)
12. Underlying medical conditions (including laboratory abnormalities) or alcohol or
drug abuse or dependence that, will be unfavorable for the administration of
treatment or affect the explanation of drug toxicity or AEs or result in
insufficient or might impair compliance with study conduct
13. Concurrent participation in another therapeutic clinical study
Gender:
All
Minimum age:
21 Years
Maximum age:
99 Years
Locations:
Facility:
Name:
National Cancer Centre Singapore
Address:
City:
Singapore
Zip:
168583
Country:
Singapore
Status:
Recruiting
Start date:
November 17, 2022
Completion date:
July 1, 2027
Lead sponsor:
Agency:
National Cancer Centre, Singapore
Agency class:
Other
Source:
National Cancer Centre, Singapore
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05517135